Survival of total hip arthroplasty (THA) in sickle cell disease.

Published in: Archives of orthopaedic and trauma surgery (2023)

Our analysis shows that THA in sickle cell disease is safe with average 12 years of follow-up, indicating that surgery in these young patients (≤ 25 years) is safe and should not be delayed.

Keyphrases

sickle cell disease
end stage renal disease
total hip arthroplasty
newly diagnosed
minimally invasive
ejection fraction
chronic kidney disease
prognostic factors
peritoneal dialysis
coronary artery bypass
coronary artery disease
percutaneous coronary intervention
acute coronary syndrome